Neurobiology and Neuropharmacology of Addiction disorders and Anxiety disorders
Research group of the Department of Psychiatry and Psychotherapy
Completed studies and papers of our FG for publication include topics such as IL-6 and S100ß as progression parameters of the depressive episode, pharmacotherapy for somatoform disorders and pharmacotherapy for emotionally unstable personality disorder of the borderline type.
Planned studies include topics such as fetal outcome of children of opioid-substituted mothers, sports therapy for posttraumatic stress disorder (PTSD) and alcohol consumption in opioid substitution patients. The first revision of the S3 guideline anxiety disorders will start in 2019.
Current projects
Current studies and projects include topics such as functional MRI in patients with panic disorder under visual and pharmacological stimulation, the use of rTMS in depressed alcohol dependent patients, biomarkers for brain atrophy in alcohol dependence, treatment variables in harmful vs. therapeutic cannabinoid use, pharmacological therapy of patients with emotionally unstable personality disorder, quality markers of psychiatric reports and exercise therapy in depressive patients. The project Metabolomics in depressives with and without cognitive deficits is currently being evaluated (Dirk Wedekind is deputy head of the biobank). Participation in the S3 guideline on drug addiction and in the Network for Alcohol-Aversive Pharmacotherapy (NAP) started in 2018 (Dirk Wedekind is 2nd chairman).
Scientific collaborations
Internal:
- RG Goya- Maldonado, Laboratory of Systems Neuroscience and Imaging in Psychiatry (SNIP-Lab)
- RG Schmidt, Traumatic Stress and Neurodegeneration
- RG Zilles-Wegner, Electroconvulsive Therapy
- UMG Children´s Cardiology
- UMG Painclinic
- UMG Neuroradiology
- UMG Clinical Neurophysiology
- UMG Neurology
External:
Addiction Clinic Brilon-Wald, Asklepios Fachklinikum Tiefenbrunn, Promotio-Göttingen
Schwerpunkte
Anxiety Disorders (Clinical Research)
Overarching Goals
Research on efficacy of treatments for anxiety disorders, in particular meta-analyses, systematic reviews of clinical studies, and guidelines for the treatment of anxiety disorders
Selection of Current Projects
Guidelines:
- German S3 guideline for anxiety disorders
- German S3 guideline: dental fear
- World Federation of Societies for Biological Psychiatry guidelines for the pharmacological treatment of anxiety disorders
Other
The S3 guideline dental fear in adults has been published on the website https://www.awmf.org/leitlinien/detail/ll/083-020.html. Prof. Borwin Bandelow has contributed to this guideline is a member of the steering group for the DGPPN.
Experimental and Clinical Addiction Research
Overarching Goals
Our focus is on neurobiological and clinical research into the causes and treatment of addictive behavior (alcohol, benzodiazepines, cannabinoids, opioids) and their concomitant and secondary psychiatric diseases (anxiety and depressive disorders, stress disorders, psychoses).
Selection of Current Projects
Leading the development of the German AWMF S3 guidelines on drug-related disorders together with Prof. A. Batra
Other
Positions and memberships of Prof. Dr. Havemann-Reinecke:
- Chairwoman of the North German Addiction Research Association NSFe.V.
- Head of the Dependency Diseases Unit of the DGPPN
- Member of the DFG Center Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB)
- Member of the Board of Directors of the German Society for Addiction Research and Therapy
- Member of the BTM commission of BfArM and BMG
- Member of the board of trustees of the German Head Office for Addiction Issues
Contact
Research Group Leader
Prof. Dr. Dirk Wedekind, M.Sc.
Tel.: +49 551 3960631
Fax.: +49 551 3960632
dirk.wedekind(at)med.uni-goettingen.de